Trial Profile
An Expanded Access Program for Neratinib in patients with HER-2 positive breast cancer or HER-2 mutated cancers
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 07 Apr 2017
Price :
$35
*
At a glance
- Drugs Neratinib (Primary)
- Indications Advanced breast cancer; Breast cancer; Early breast cancer; HER2 positive breast cancer; Solid tumours
- Focus Expanded access; Therapeutic Use
- 07 Apr 2017 New trial record